Clinical trials
Completed Stress Disorders, Post-Traumatic trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 3 |
| 2009 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 7 |
| 2021 | 12 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 60 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Manitoba | 7 |
| Centre for Addiction and Mental Health | 5 |
| McMaster University | 4 |
| Resilient Pharmaceuticals | 4 |
| Toronto Metropolitan University | 3 |
| University Health Network, Toronto | 3 |
| IWK Health Centre | 2 |
| Laval University | 2 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2 |
| St. Joseph's Healthcare Hamilton | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stress Disorders, Post-Traumatic | 60 |
| Anxiety Disorders | 17 |
| COVID-19 | 4 |
| Major Depressive Disorder | 4 |
| Wounds and Injuries | 4 |
| Depressive Disorder | 3 |
| Substance-Related Disorders | 3 |
| Dysthymic Disorder | 2 |
| Generalized Anxiety Disorder | 2 |
| Obsessive-Compulsive Disorder | 2 |
Trials
Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.